Correlation Engine 2.0
Clear Search sequence regions

  • blood (4)
  • cohort studies (1)
  • data sources (1)
  • GFAP (1)
  • humans (1)
  • IL 6 (1)
  • IL 8 (1)
  • IP 10 (1)
  • MCP 1 (1)
  • patients (3)
  • pilot studies (1)
  • prognostic (2)
  • S100b (1)
  • spinal cord (8)
  • TNF α (1)
  • Sizes of these terms reflect their relevance to your search.

    Objective. To examine (1) if serological or cerebrospinal fluid (CSF) biomarkers can be used as diagnostic and/or prognostic tools in patients with spinal cord injury (SCI) and (2) if literature provides recommendations regarding timing and source of biomarker evaluation. Data Sources. A systematic literature search to identify studies reporting on diagnostic and prognostic blood and/or CSF biomarkers in SCI was conducted in PubMed/MEDLINE, CINAHL, Science Direct, The Cochrane Library, ISI Web of Science, and PEDro. Study Selection. Clinical trials, cohort, and pilot studies on patients with traumatic SCI investigating at least one blood or CSF biomarker were included. Following systematic screening, 19 articles were included in the final analysis. PRISMA guidelines were followed to conduct this review. Data Extraction. Independent extraction of articles was completed by 2 authors using predefined inclusion criteria and study quality indicators. Data Synthesis. Nineteen studies published between 2002 and April 2019 with 1596 patients were included in the systematic review. In 14 studies, blood biomarkers were measured, 4 studies investigated CSF biomarkers, and 1 study used both blood and CSF samples. Conclusions. Serum/CSF concentrations of several biomarkers (S100b, IL-6, GFAP, NSE, tau, TNF-α, IL-8, MCP-1, pNF-H, and IP-10) following SCI are highly time dependent and related to injury severity. Future studies need to validate these markers as true biomarkers and should control for secondary complications associated with SCI. A deeper understanding of secondary pathophysiological events after SCI and their effect on biomarker dynamics may improve their clinical significance as surrogate parameters in future clinical studies.


    Iris Leister, Thomas Haider, Georg Mattiassich, John L K Kramer, Lukas D Linde, Adnan Pajalic, Lukas Grassner, Barbara Altendorfer, Herbert Resch, Stephanie Aschauer-Wallner, Ludwig Aigner. Biomarkers in Traumatic Spinal Cord Injury-Technical and Clinical Considerations: A Systematic Review. Neurorehabilitation and neural repair. 2020 Feb;34(2):95-110

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 31971869

    View Full Text